Alexandra Sinclair Email

Chief Scientific Officer, Previous Executive Director, Founder . Invex Therapeutics

Current Roles

Employees:
7
Revenue:
$1.1M
About
Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendinâ„¢.
Invex Therapeutics Address
38 Rowland Street
Subiaco, WA
Invex Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.